Abiopharma

🔍 Green Kevin Dennis (Executive)

Company: CERUS CORP (CERS)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Acquired 63,854 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: false | shares_owned_after: 1,251,116.00 | transaction_form_type: 4
• Sold 55,225 shares of Common Stock at $2.0625 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: false | shares_owned_after: 1,195,891.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 27,796 shares of Common Stock at $2.0055 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: false | shares_owned_after: 1,168,095.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: This transaction was executed pursuant to a 10b5-1 plan.
• F2: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.015 to $2.17 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
• F3: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.
• F4: Represents a weighted average sales price. These shares were sold in multiple transactions in a block trade transaction. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price in the block trade.